The Association of Polymyalgia Rheumatica and Giant Cell Arteritis With COVID-19 Vaccination: A Systematic Review.

IF 1.9 Q2 ORTHOPEDICS
Fatima Shahid, Hareem Farooq, Huzaifa Abeer, Ghulam Mustafa Mahmood, Habibah Sheikh, Muhammad Zain Ameer, Laveeza Fatima, Fatima Ameer, Zunaira Amjad, Talha Zartash Ahmad, Ghazia Rehman, Aqeeb Ur Rehman
{"title":"The Association of Polymyalgia Rheumatica and Giant Cell Arteritis With COVID-19 Vaccination: A Systematic Review.","authors":"Fatima Shahid, Hareem Farooq, Huzaifa Abeer, Ghulam Mustafa Mahmood, Habibah Sheikh, Muhammad Zain Ameer, Laveeza Fatima, Fatima Ameer, Zunaira Amjad, Talha Zartash Ahmad, Ghazia Rehman, Aqeeb Ur Rehman","doi":"10.1177/11795441251414673","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are interrelated inflammatory conditions, and evidence suggests that infection and vaccination might act as a trigger for these conditions. This descriptive systematic review summarizes the published case reports and case series on new-onset PMR and GCA following COVID-19 vaccination, highlighting their clinical features, diagnostic findings, and treatment outcomes.</p><p><strong>Objectives: </strong>To do a systematic analysis of available literature regarding the association between COVID-19 vaccination and the first onset or flare of PMR and/or GCA.</p><p><strong>Design: </strong>Systematic review of case reports and case series.</p><p><strong>Data sources and methods: </strong>A systematic literature search was conducted using PubMed/MEDLINE, Cochrane, ScienceDirect, and Google Scholar. Data on patient demographics, clinical features, outcomes, and latency periods were extracted and analyzed. Quality assessment of included studies was performed using the Joanna Briggs Institute Critical Appraisal Tool.</p><p><strong>Results: </strong>A total of 32 articles, documenting 50 new-onset cases (30 PMR and 20 GCA), were identified for inclusion. The mean age for patients with PMR was 71.06 years, and 72.85 years for GCA. A slight female predominance was observed (60%) for both PMR and GCA. Pfizer-BioNTech (48%) and AstraZeneca (38%) vaccines were most frequently associated with disease onset. The mean latency period from vaccination to symptom onset was 11.03 days for PMR and 5.3 days for GCA, indicating a temporal relationship. Most of these studies originated from North America and Europe mimicking the global scale of vaccination. Most patients responded well to symptomatic treatment with corticosteroids.</p><p><strong>Conclusions: </strong>There exists a temporal association between COVID-19 mRNA or viral vector-based vaccines and the onset of PMR and GCA. While causality is not proven, this review underscores the need for clinicians to be aware of this potential association to ensure timely diagnosis and treatment, particularly as booster vaccinations continue to be administered. Larger epidemiological studies with long-term follow-up are essential to further explore this association.</p>","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"19 ","pages":"11795441251414673"},"PeriodicalIF":1.9000,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12816559/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795441251414673","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are interrelated inflammatory conditions, and evidence suggests that infection and vaccination might act as a trigger for these conditions. This descriptive systematic review summarizes the published case reports and case series on new-onset PMR and GCA following COVID-19 vaccination, highlighting their clinical features, diagnostic findings, and treatment outcomes.

Objectives: To do a systematic analysis of available literature regarding the association between COVID-19 vaccination and the first onset or flare of PMR and/or GCA.

Design: Systematic review of case reports and case series.

Data sources and methods: A systematic literature search was conducted using PubMed/MEDLINE, Cochrane, ScienceDirect, and Google Scholar. Data on patient demographics, clinical features, outcomes, and latency periods were extracted and analyzed. Quality assessment of included studies was performed using the Joanna Briggs Institute Critical Appraisal Tool.

Results: A total of 32 articles, documenting 50 new-onset cases (30 PMR and 20 GCA), were identified for inclusion. The mean age for patients with PMR was 71.06 years, and 72.85 years for GCA. A slight female predominance was observed (60%) for both PMR and GCA. Pfizer-BioNTech (48%) and AstraZeneca (38%) vaccines were most frequently associated with disease onset. The mean latency period from vaccination to symptom onset was 11.03 days for PMR and 5.3 days for GCA, indicating a temporal relationship. Most of these studies originated from North America and Europe mimicking the global scale of vaccination. Most patients responded well to symptomatic treatment with corticosteroids.

Conclusions: There exists a temporal association between COVID-19 mRNA or viral vector-based vaccines and the onset of PMR and GCA. While causality is not proven, this review underscores the need for clinicians to be aware of this potential association to ensure timely diagnosis and treatment, particularly as booster vaccinations continue to be administered. Larger epidemiological studies with long-term follow-up are essential to further explore this association.

风湿性多肌痛和巨细胞动脉炎与COVID-19疫苗接种的关系:一项系统综述
背景:风湿性多肌痛(PMR)和巨细胞动脉炎(GCA)是相互关联的炎症,有证据表明感染和疫苗接种可能是这些疾病的触发因素。本描述性系统综述总结了已发表的COVID-19疫苗接种后新发PMR和GCA的病例报告和病例系列,强调了其临床特征、诊断结果和治疗结果。目的:对有关COVID-19疫苗接种与PMR和/或GCA首次发病或发作之间关系的现有文献进行系统分析。设计:系统回顾病例报告和病例系列。数据来源和方法:使用PubMed/MEDLINE、Cochrane、ScienceDirect和谷歌Scholar进行系统文献检索。提取和分析患者人口统计学、临床特征、结局和潜伏期的数据。采用乔安娜布里格斯研究所关键评估工具对纳入的研究进行质量评估。结果:共纳入32篇文章,记录了50例新发病例(30例PMR和20例GCA)。PMR患者平均年龄为71.06岁,GCA患者平均年龄为72.85岁。PMR和GCA均有轻微的女性优势(60%)。辉瑞- biontech(48%)和阿斯利康(38%)疫苗最常与疾病发病相关。从接种疫苗到症状出现的平均潜伏期,PMR为11.03天,GCA为5.3天,显示出时间关系。这些研究大多来自北美和欧洲,模仿全球规模的疫苗接种。大多数患者对皮质类固醇对症治疗反应良好。结论:COVID-19 mRNA或病毒载体疫苗与PMR和GCA的发病存在时间相关性。虽然因果关系尚未得到证实,但本综述强调临床医生需要意识到这种潜在的关联,以确保及时诊断和治疗,特别是在继续进行加强疫苗接种的情况下。更大规模的长期随访流行病学研究对于进一步探索这种关联至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.40
自引率
0.00%
发文量
14
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书